Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2019

View Archived Issues

Size matters in RNA-seq analyses

Anti-Siglec-15 monoclonal antibody NC-318 well tolerated and active in first-in-human study

IND approval and patent application for the first-ever liquid formulation of topiramate

Results presented from ongoing phase I/II study of IDE-196

ZGN-1345 demonstrates promise in preclinical models of NASH and HCC

Phase II data presented for ziltivekimab in hemodialysis patients

SARA as a potential new therapeutic target in human chronic kidney disease

New FFA1 agonist derived from an old scaffold shows potential for treatment of type 2 diabetes

Gut microbiota dysbiosis promotes neuroinflammation in Alzheimer's disease progression

Discovery of new potent NS4B inhibitor, JMX-0254

Rat homologue of FX-201 decreases incidence and severity of osteoarthritis-related lesions

TLN1 gene mutations linked to human nephrotic syndrome

Redox repositioning reaps benefits in TB treatment

Truncated ACE2 fusion protein targets RAS overactivity in renal diseases

Data on peripheral immune responses to selgantolimod from phase II study in HBV reported

L-FABP levels correlated with sarcopenia measures in diabetic kidney disease

Eternity Bioscience patents RORC antagonists

Bristol-Myers Squibb discloses new UFO and MERTK inhibitors

Rigel Pharmaceuticals synthesizes RIPK1 inhibitors

Enanta Pharmaceuticals describes new MAP3K5 inhibitors

Kinnate Biopharma patents CDK inhibitors

FDA approves Givlaari for acute hepatic porphyria

New phase I study evaluates bispecific PSMAxCD3 antibody CC-1 in CRPC

Arcutis begins phase II study of ARQ-154 foam for seborrheic dermatitis

Phoenix Molecular initiates first-in-human study of PMD-026 in advanced breast cancer

FDA approves phase I/II trial of Hope's adipose-derived mesenchymal stem cells for Alzheimer's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...